Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 8,909 |
|
|||||
| News | - | ||||||
| Day High | 2.54 | Low High |
|||||
| Day Low | 2.42 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VYNE Therapeutics Inc | VYNE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.048 | -1.94% | 2.422 | 12:12:53 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.47 | 2.42 | 2.54 | 2.47 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 116 | 8,909 | $ 2.49 | $ 22,144 | - | 1.67 - 8.81 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:12:53 | 200 | $ 2.422 | USD |
VYNE Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 35.25M | 14.10M | - | 424k | -28.45M | -2.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
VYNE Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VYNE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.26 | 2.80 | 2.24 | 2.52 | 107,774 | 0.162 | 7.17% |
| 1 Month | 3.13 | 3.17 | 2.24 | 2.76 | 97,411 | -0.708 | -22.62% |
| 3 Months | 1.80 | 3.17 | 1.77 | 2.49 | 109,803 | 0.622 | 34.56% |
| 6 Months | 2.40 | 4.4808 | 1.67 | 2.69 | 266,346 | 0.022 | 0.92% |
| 1 Year | 4.29 | 8.81 | 1.67 | 3.07 | 150,036 | -1.87 | -43.54% |
| 3 Years | 93.60 | 98.46 | 1.67 | 19.50 | 715,650 | -91.18 | -97.41% |
| 5 Years | 106.56 | 237.60 | 1.67 | 96.01 | 1,250,994 | -104.14 | -97.73% |
VYNE Therapeutics Description
| VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. |
